Evidence map›Paper›PMID 18207302›Full record

ReviewProgress in neurobiology2008

Progress in neuroprotective strategies for preventing epilepsy.

Munjal M Acharya, Bharathi Hattiangady, Ashok K Shetty

Abstract readReview
In one paragraph

Review in Progress in neurobiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 183 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Baicalein Exerts Neuroprotective Effects in FeClFrontiers in pharmacology · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Munjal M AcharyaMedical Research and Surgery Services, Veterans Affairs Medical Center, Durham, NC 27705, USA.
Bharathi Hattiangady
Ashok K Shetty
Duke University Hospital · USDuke Medical Center · US

Funding

Behavior of Stem Cells in the Lesioned Aging HippocampusR01AG020924 · NIA · DUKE UNIVERSITY · PI SHETTY, ASHOK K. · 2002 to 2006
$1.5M
Neural Grafts and Injury-Induced Hippocampal DysfunctionR01NS054780 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SHETTY, ASHOK K · 2006 to 2010
$1.4M
Repair of Chronially Injured Hippocampus by GraftsR01NS043507 · NINDS · DUKE UNIVERSITY · PI SHETTY, ASHOK K. · 2003 to 2006
$1.3M
AHRQ HHS R01 HS029482NIA NIH HHS AG 20924NIA NIH HHS R01 AG020924NINDS NIH HHS NS 043507NINDS NIH HHS NS 054780NINDS NIH HHS R01 NS043507NINDS NIH HHS R01 NS054780
6 · The paper itself

Abstract

Neuroprotection is increasingly considered as a promising therapy for preventing and treating temporal lobe epilepsy (TLE). The development of chronic TLE, also termed as epileptogenesis, is a dynamic process. An initial precipitating injury (IPI) such as the status epilepticus (SE) leads to neurodegeneration, abnormal reorganization of the brain circuitry and a significant loss of functional inhibition. All of these changes likely contribute to the development of chronic epilepsy, characterized by spontaneous recurrent motor seizures (SRMS) and learning and memory deficits. The purpose of this review is to discuss the current state of knowledge pertaining to neuroprotection in epileptic conditions, and to highlight the efficacy of distinct neuroprotective strategies for preventing or treating chronic TLE. Although the administration of certain conventional and new generation anti-epileptic drugs is effective for primary neuroprotection such as reduced neurodegeneration after acute seizures or the SE, their competence for preventing the development of chronic epilepsy after an IPI is either unknown or not promising. On the other hand, alternative strategies such as the ketogenic diet therapy, administration of distinct neurotrophic factors, hormones or antioxidants seem useful for preventing and treating chronic TLE. However, long-term studies on the efficacy of these approaches introduced at different time-points after the SE or an IPI are lacking. Additionally, grafting of fetal hippocampal cells at early time-points after an IPI holds considerable promise for preventing TLE, though issues regarding availability of donor cells, ethical concerns, timing of grafting after SE, and durability of graft-mediated seizure suppression need to be resolved for further advances with this approach. Overall, from the studies performed so far, there is consensus that neuroprotective strategies need to be employed as quickly as possible after the onset of the SE or an IPI for considerable beneficial effects. Nevertheless, ideal strategies that are capable of facilitating repair and functional recovery of the brain after an IPI and preventing the evolution of IPI into chronic epilepsy are still hard to pin down.

Indexed as

AnimalsAnticonvulsantsBrainChronic DiseaseDiet, Carbohydrate-RestrictedDiet TherapyEpilepsy, Temporal LobeHumansKetone BodiesNeuronsNeuroprotective AgentsAnticonvulsantsKetone BodiesNeuroprotective Agents

Identifiers

PMID18207302
PMCPMC2441599
OpenAlexW2050736164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.